Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

The Company is enrolled to participate in the Patent Prosecution Highway (PPH), a program to fast-track patent examination in major jurisdictions including the U.S., Europe and Japan. Since IP Australia has allowed patent application 2022384750, Conduit believes it is more likely to receive subsequent approvals in other markets. Patents in these major countries are the most sought after and valuable patents for marketed drug products, providing up to 20 years of patent protection. Conduit Pharmaceuticals (N ...